Jelle A Spoorendonk

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Positive Breast Cancer

Gene Expression

Sentinel Lymph Node

Top Venues

Journal of medical economics

International journal of breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, Tim Ignacio, Pieter B Drost, Tim Jacobs, Felix E deJongh
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands. Journal of medical economics 27 (1) (2024)
Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, Tim Ignacio, Pieter B Drost, Tim Jacobs, Felix E deJongh
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands. Journal of medical economics (2024)
Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, Tim Ignacio, Pieter B Drost, Tim Jacobs, Felix E deJongh
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands. Journal of medical economics 27 (1) (2024)
Felix E de Jongh, Reva Efe, Kirsten H Herrmann, Jelle A Spoorendonk
Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International journal of breast cancer 2022 (2022)